Literature DB >> 1679034

Genetic heterogeneity of the porphobilinogen deaminase gene in Swedish families with acute intermittent porphyria.

J S Lee1, G Lundin, L Lannfelt, L Forsell, C Picat, B Grandchamp, M Anvret.   

Abstract

Acute intermittent porphyria (AIP) is an autosomal dominant metabolic disorder affecting the enzyme porphobilinogen (PBG) deaminase in the heme biosynthetic pathway. The highest prevalence of the disorder has been observed in Scandinavia, especially in northern Sweden (Lappland) where it occurs with a prevalence of 1 in 1500. Biochemical assays of the activity and concentration of PBG deaminase in red blood cells, haplotyping with 4 intragenic restriction fragment length polymorphisms (RFLPs) (MspI, PstI, BstNI, ApaLI) using the polymerase chain reaction (PCR) and screening for known base substitutions by oligonucleotide probes was performed in 28 Swedish AIP families. There was no close relationship between haplotype, biochemical findings (PBG deaminase activity, enzyme-linked immunosorbent assay [ELISA], and excess urinary excretion of delta-aminolevulinic acid or PBG), and a specific mutation. Three different haplotypes were identified. The haplotype 2/1/1/2 (MspI/PstI/BstNI/ApaLI; +/-/-/+) was found to be the most frequent among gene carriers (P less than 0.001). The disease segregated with the haplotype 2/1/1/2 in the 10 families originating from northern Sweden. All 28 families were screened for three known point mutations. Only one was found to carry one of these mutations. Thus, the genetic background of AIP is heterogeneous in Sweden.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679034     DOI: 10.1007/bf00197173

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  23 in total

Review 1.  DNA diagnostics--molecular techniques and automation.

Authors:  U Landegren; R Kaiser; C T Caskey; L Hood
Journal:  Science       Date:  1988-10-14       Impact factor: 47.728

2.  Variant of acute intermittent porphyria with normal erythrocyte uroporphyrinogen-I-synthase activity.

Authors:  P Mustajoki; R Tenhunen
Journal:  Eur J Clin Invest       Date:  1985-10       Impact factor: 4.686

3.  Acute intermittent porphyria: characterization of a novel mutation in the structural gene for porphobilinogen deaminase. Demonstration of noncatalytic enzyme intermediates stabilized by bound substrate.

Authors:  R J Desnick; L T Ostasiewicz; P A Tishler; P Mustajoki
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

4.  A PstI polymorphism for the human porphobilinogen deaminase gene (PBG).

Authors:  J S Lee; M Anvret
Journal:  Nucleic Acids Res       Date:  1987-08-11       Impact factor: 16.971

5.  Two different point G to A mutations in exon 10 of the porphobilinogen deaminase gene are responsible for acute intermittent porphyria.

Authors:  M H Delfau; C Picat; F W de Rooij; K Hamer; M Bogard; J H Wilson; J C Deybach; Y Nordmann; B Grandchamp
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

6.  Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase.

Authors:  B Grandchamp; C Picat; R Kauppinen; V Mignotte; L Peltonen; P Mustajoki; P H Roméo; M Goossens; Y Nordmann
Journal:  Eur J Clin Invest       Date:  1989-10       Impact factor: 4.686

7.  DNA polymorphism of human porphobilinogen deaminase gene in acute intermittent porphyria.

Authors:  D H Llewellyn; G H Elder; N A Kalsheker; O W Marsh; P R Harrison; B Grandchamp; C Picat; Y Nordmann; P H Romeo; M Goossens
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

Review 8.  Diagnosis of genetic disorders at the DNA level.

Authors:  S E Antonarakis
Journal:  N Engl J Med       Date:  1989-01-19       Impact factor: 91.245

9.  ELISA for measuring porphobilinogen deaminase in human erythrocytes.

Authors:  L Lannfelt; L Wetterberg; L Lilius; S Thunell; P Gellerfors
Journal:  Clin Chim Acta       Date:  1989-08-15       Impact factor: 3.786

10.  Studies in porphyria. IV. Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: prenatal diagnosis of the porphyric trait.

Authors:  S Sassa; G Solish; R D Levere; A Kappas
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

View more
  6 in total

1.  Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP).

Authors:  C Solis; I Lopez-Echaniz; D Sefarty-Graneda; K H Astrin; R J Desnick
Journal:  Mol Med       Date:  1999-10       Impact factor: 6.354

2.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

Review 3.  Molecular genetics of disorders of haem biosynthesis.

Authors:  G H Elder
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

Review 4.  Porphobilinogen deaminase gene structure and molecular defects.

Authors:  J C Deybach; H Puy
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

5.  Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria.

Authors:  J S Lee; M Anvret
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

6.  No association between RFLPs at the porphobilinogen deaminase gene and schizophrenia.

Authors:  M J Owen; R Mant; E Parfitt; J Williams; P Asherson; G O'Mahoney; J Van Os; D Llewellyn; D Collier; M Gill
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.